Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

Overview of attention for article published in Lancet Oncology, June 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 6 news outlets
twitter: 92 X users

f1000: 1 research highlight platform

Citations

dimensions_citation: 453 Dimensions

Readers on

mendeley: 469 Mendeley
citeulike: 1 CiteULike

Summary News X Research highlights Dimensions citations

So far, Altmetric has seen 1 review on a research highlight platform.

Recommended in Faculty Opinions

29 Apr 2020

This research output was recommended by a member of Faculty Opinions.

This page shows the most recent research highlights that mention this research output.

Click here to find out how to access more activity.